Searchable abstracts of presentations at key conferences in endocrinology

ea0003p23 | Clinical Case Reports | BES2002

Glucocorticoid remediable aldosteronism. A Northern Ireland experience

McLaughlin D , Harper R , Inglis G , Connell J , Sheridan B , Atkinson A

Glucocorticoid remediable aldosteronism (GRA) was first described in 1966 by Sutherland et ala. In this family, aldosterone secretion was regulated by ACTH and symptoms and signs were reversed by the administration of exogenous glucocorticoid. GRA is usually characterised by moderate to severe hypertension with early onset. The hypertension is often difficult to control and is associated with greatly increased vascular risk. It is inherited as an autosomal dominant trait and ...

ea0027s15 | RCN CYP Diabetes Community Session | BSPED2011

Diabetes self-management education: can it change diabetes outcomes?

Waldron Sheridan

Diabetes self-management education (DSME) in the UK is less well defined in paediatrics than in adults. Moreover, there is no nationally validated programme of education for paediatrics consequently the 70% of services that offer structured education have developed them locally. As we move towards a new system of payment for paediatric diabetes, the Best Practice Tariff, services will need to demonstrate that they supply a structured education programme from diagnosis and thro...

ea0007p212 | Steroids | BES2004

Role of PPAR-gamma receptor agonist therapy in two patients with newly diagnosed pituitary-dependent Cushing's syndrome

Hull S , Sheridan B , Atkinson A

Existing treatments for pituitary-dependent Cushing's Syndrome include pituitary or adrenal surgery, pituitary irradiation and medical therapy. Pituitary microsurgery is the usual therapy of first choice but is not always successful in achieving early apparent remission and is associated with significant late relapses. An effective drug therapy for humans would be a major advance as there is significant morbidity and mortality in Cushing's Syndrome. Recent elegant in vitro and...

ea0003p38 | Clinical Case Reports | BES2002

Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with octreotide in the absence of marked tumour shrinkage. A reason for cautious optimism ?

Harding J , Sheridan B , Atkinson A

A 45-year-old lady presented with a 12-month history of blurred vision. Visual assessment revealed a bitemporal hemianopia and CT scan demonstrated a large pituitary tumour with lateral and suprasellar extension. A GTT showed her growth hormone was raised basally at 7.5 milliunits per litre and incompletely suppressed to 5.7 milliunits per litre confirming acromegaly. Transsphenoidal hypophysectomy was performed. Histology confirmed a somatoptroph adenoma. Post operatively she...

ea0003p39 | Clinical Case Reports | BES2002

Hyperprolactinaemia in a patient taking the herbal remedy Agnus Castus

Harding J , Sheridan B , Atkinson A

A 34-year-old woman, presented to her General Practitioner with hot flushes. Investigations showed her to have a normal LH, FSH, free T4 and TSH. Her prolactin was elevated at 1110 milliunits per litre (NR <350 ). She had a normal menarche age 14 and had regular 28 day menstrual cycles. Before the onset of the hot flushes she had started to take agnus castus, a herbal remedy said to help symptoms of premenstrual tension.Whilst she continued to take ...

ea0038p340 | Pituitary | SFEBES2015

An unusual case of acromegaly

Sheridan Mia , Turtle Emma , Van Look Liesbeth

A 57-year-old woman presented with a 4-week history of lethargy, weight loss, polyuria, and polydipsia. Her only past medical history of note was hypertension for which she was taking lisinopril. On admission her initial investigations showed: glucose 22.6 mmol/l, capillary blood ketones Hi and a metabolic acidosis (H+57.5 nmol/l and HCO3− 13.7 mmol/l). She was commenced on the DKA protocol and her acidosis resolved without complication. She was maintained on ...

ea0003p28 | Clinical Case Reports | BES2002

Cushing's syndrome of indeterminate origin. Sucessful treatment of a liver abscess after therapy with a block and replacement medical regimen

Harding J , Kennedy A , Sheridan B , Atkinson A

A 67 yr old lady was admitted with left ventricular failure, angina, and atrial fibrillation. She was hypokalaemic (2.5mmol/l). There was a 3 year history of hypertension and a new diagnosis of diabetes mellitus. There was a recent history of weight gain, muscle weakness, bruising and facial puffiness. On examination she appeared cushingoid. A 24 hour urine for free cortisol was 1438nmol\/24h (normal<350). A basal 0800h serum cortisol was 1061nmol/l. After low dose dexameth...

ea0086p216 | Metabolism, Obesity and Diabetes | SFEBES2022

Simvastatin regulates Il10 gene expression in male and female murine macrophages

Sheridan Alanah , Wheeler-Jones Caroline , Gage Matthew C.

Statins are among the most widely prescribed medications worldwide, decreasing the risk of cardiovascular diseases by reducing cholesterol levels. However, statins also increase the risk of incident type 2 diabetes (T2D), disproportionately affecting women compared to men. Inflammation has emerged as a central factor underpinning T2D pathology, with macrophages playing a significant role. Statins have been found to influence macrophage inflammatory responses, and this has been...

ea0011p741 | Steroids | ECE2006

Can the 250mcg synacthen test be used to screen for primary hyperaldosteronism?

Mullan K , Leslie H , Sheridan B , Atkinson AB

Primary hyperaldosteronism secondary to bilateral adrenal hyperplasia (BAH) bears striking similarities pathophysiologically to essential hypertension. During stimulation studies to elucidate possible aberrant aldosterone responses in BAH we measured the aldosterone response to 250mcg iv synacthen after 30 and 60 minutes in 7 patients with BAH and in 20 healthy controls. Patients had diuretics withheld for at least 4 weeks and betablockers and calcium channel blockers withheld...

ea0011p756 | Steroids | ECE2006

The glucocorticoid receptor 1a promoter in CD4+CD8+ thymocytes is rapidly upregulated following dexamethasone treatment in vitro

Nixon J , Sheridan J , Blackburn C , Chapman K

Glucocorticoid Receptor (GR) levels are increased in response to glucocorticoids (GC) in T-lymphoma cell lines susceptible to GC-induced cell death (GICD). The GR gene is transcribed from 5 promoters generating alternate first exons, 1A-1E, with 1A expression restricted to immune tissue and the cortex of the brain. Expression of the 1A-containing variant correlates with susceptibility to GICD in mouse thymocytes. Here we describe the time course of GC induction of total GR mRN...